Complete Response Letters

Accord Healthcare Inc.: bendamustine hydrochloride

What FDA's Complete Response Letters to the company say, in the letters' own words.

EphemerisX Research · Sep 30, 2026 · Sources: FDA, SEC

Complete Response Letter, Nov 6, 2025

The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA 483 prior to your complete response.

Complete Response Letter · Nov 6, 2025 · p. 2Open the letter at p. 2 ↗CRL_NDA216987_20251106:p1:s20

FDA office indicated on the FDA 483 prior to your complete response.

Complete Response Letter · Dec 5, 2024 · p. 1Open the letter at p. 1 ↗CRL_NDA218762_20241205:p1:s33

No complete sentence from this letter is available from the knowledge graph yet.

No complete sentence from this letter is available from the knowledge graph yet.

No complete sentence from this letter is available from the knowledge graph yet.

No complete sentence from this letter is available from the knowledge graph yet.

Food, Drug, and Cosmetic Act for Carmustine for injection.

Complete Response Letter · Apr 30, 2021 · p. 2Open the letter at p. 2 ↗CRL_NDA215000_20210430:p1:s13

'ake before the application may be approved.

Complete Response Letter · Apr 30, 2021 · p. 5Open the letter at p. 5 ↗CRL_NDA215000_20210430:p2:s12

Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.